India Ni Gelukutunna America

[JavaBava]

This is regular shit .. india kuda cases estadi like against subsidy given to US farmers by us govt.

[TheWall]

kani Ranbaxy vadu mandu ki badulu edo powder petti ammesadani talk vacchindi ?

donno abt this particular case kani nenu oka sari chadiva about a professor/doctor who is trying to expose all these....article dorikithe ill share 

[paampachak]

Our companies can sell producrs for much cheaper rates in international market. This is against fair trade policy

 

yes when US can pay cheap rates to our software guys that is so fair na

[galiraju]

donno abt this particular case kani nenu oka sari chadiva about a professor/doctor who is trying to expose all these....article dorikithe ill share 

http://www.youtube.com/watch?v=cq3S98_m5Fk

[TheWall]

http://www.youtube.com/watch?v=cq3S98_m5Fk

intikellaka soostha 

[galiraju]

In 2005, the FDA granted approval for a promising new cancer-fighting drug called Nexavar. Bayer took it to market shortly thereafter, and it is currently an approved treatment for late-stage kidney and liver cancer.

That is, so long as you live in the developed world. During a panel at a Financial Times conference last month, Bayer CEO Marijn Dekkers appeared to suggest that his company’s life-saving drug isn’t for poor people. The comment was first reported by Bloomberg Businessweek:

“Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product.”

The comment was in response to a decision by an Indian patent court that granted a compulsory license to a local company to reproduce Bayer’s drug. Under Indian patent laws, if a product is not available locally at a reasonable cost, other companies may apply for licenses to reproduce those products at a more affordable price. Nexavar costs an estimated $69,000 for a full year of treatment in India, 41 times the country’s annual per capita income.

In 2012, Indian pharmaceutical company Natco Pharma Ltd. applied for just such a license, and it was granted. The company began reproducing the drug at a 97 percent discount, offering it for just $177. Bayer has been appealing the ruling ever since, and in December Dekkers told Businessweek that he viewed the compulsory license as “essentially theft” before dismissing poor Indian cancer patients.

Pharmaceutical companies have long been accused of ignoring the plight of those who cannot afford their astronomical prices. In the United States, where insurance companies often pick up most of the tab, consumers are often shielded from the true cost of drugs they are prescribed (Nexavar, for example, costs as much as $96,000 in the United States, butBayer ensures that eligible US patients only see a $100 copay).

Dekkers’ quote brings into sharp relief the industry’s general ambivalence towards the developing world. A 2012 report from Doctors Without Borders found that most pharmaceutical companies devote only a small fraction of their operating budgets to fighting diseases that disproportionally affect — and kill — millions of the world’s poorest people.

[cherlapallifailure]

picha lite.... political game.... what is more important is empowerment of rural women and execution of rti 

[Akkumm_Bakkumm]

http://www.nytimes.com/2013/09/17/business/us-bans-import-of-ranbaxy-drug-made-in-india.html?_r=0

 

generic drugs ante konchem cheap untai ... but they have the same effect .... kani avi vaadithe imports perigi local pharma ki paisal ravani they banned imports

 

Usually Generics mida eppudina konni rojulu ban untundi mayya, endukante oka pharma company oka drug develop chesi approve cheyyadaniki chala invest chestaru so pharma money make cheskovadam kosam konni years generics ni manufacture cheyyakunda chustaru but daniki oka time limit untundi.  

[JavaBava]

WTO sogn cheste we have to follow rhe rules
..no one should compete in international market with govt subsidies ... we should compete and deliver cheaper products only through innovation .. toyota meda case eyyakudadu cheaper products ani
.they have done it through techmology and innovation. Tats valid. Subsidies are not valid.

[cherlapallifailure]

andukane WI ni stapinchale

[paampachak]

WTO sogn cheste we have to follow rhe rules
..no one should compete in international market with govt subsidies ... we should compete and deliver cheaper products only through innovation .. toyota meda case eyyakudadu cheaper products ani
.they have done it through techmology and innovation. Tats valid. Subsidies are not valid.

 

sounds good. my point here is about vested interests.
 

[TheWall]

 

In 2005, the FDA granted approval for a promising new cancer-fighting drug called Nexavar. Bayer took it to market shortly thereafter, and it is currently an approved treatment for late-stage kidney and liver cancer.

That is, so long as you live in the developed world. During a panel at a Financial Times conference last month, Bayer CEO Marijn Dekkers appeared to suggest that his company’s life-saving drug isn’t for poor people. The comment was first reported by Bloomberg Businessweek:

“Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product.”

The comment was in response to a decision by an Indian patent court that granted a compulsory license to a local company to reproduce Bayer’s drug. Under Indian patent laws, if a product is not available locally at a reasonable cost, other companies may apply for licenses to reproduce those products at a more affordable price. Nexavar costs an estimated $69,000 for a full year of treatment in India, 41 times the country’s annual per capita income.

In 2012, Indian pharmaceutical company Natco Pharma Ltd. applied for just such a license, and it was granted. The company began reproducing the drug at a 97 percent discount, offering it for just $177. Bayer has been appealing the ruling ever since, and in December Dekkers told Businessweek that he viewed the compulsory license as “essentially theft” before dismissing poor Indian cancer patients.

Pharmaceutical companies have long been accused of ignoring the plight of those who cannot afford their astronomical prices. In the United States, where insurance companies often pick up most of the tab, consumers are often shielded from the true cost of drugs they are prescribed (Nexavar, for example, costs as much as $96,000 in the United States, butBayer ensures that eligible US patients only see a $100 copay).

Dekkers’ quote brings into sharp relief the industry’s general ambivalence towards the developing world. A 2012 report from Doctors Without Borders found that most pharmaceutical companies devote only a small fraction of their operating budgets to fighting diseases that disproportionally affect — and kill — millions of the world’s poorest people.

 

chillar lk gallu.... 

[TheWall]

Usually Generics mida eppudina konni rojulu ban untundi mayya, endukante oka pharma company oka drug develop chesi approve cheyyadaniki chala invest chestaru so pharma money make cheskovadam kosam konni years generics ni manufacture cheyyakunda chustaru but daniki oka time limit untundi.  

not just generics maayya....there are some tablets in India...exact make and dosage which costs cheaper in India without insurance than in US with insurance..... 

[macha]

Mari us entha top loo ela undi economically ? This are all kutra done by gov... 1960 la water tho nadichey engine ... upto 200 mpg cars 1980 la food market monopoly now in lot more fingerings and taking control ...

[paampachak]

not just generics maayya....there are some tablets in India...exact make and dosage which costs cheaper in India without insurance than in US with insurance..... 

 

ne monna warts ki cream konte 570$ aindi India lo adi 2000Rs